Advanced Drug Delivery Systems in Management of Chronic Obstructive Pulmonary Disease
CRC Press (Verlag)
978-1-032-81259-5 (ISBN)
- Noch nicht erschienen (ca. März 2025)
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
This book offers a comprehensive overview of the epidemiology, etiology, and pathophysiology of Chronic Obstructive Pulmonary Disease (COPD). It addresses the limitations of existing drug delivery methods and explores advanced delivery systems to overcome these challenges, providing an exhaustive account of their intricate mechanisms. The introductory chapters elucidate pathways responsible for COPD progression, followed by a detailed analysis of established biomarkers and potential targets in contemporary COPD therapy. Subsequent chapters provide insights into ongoing treatment modalities, their efficacy, drawbacks, and prospective solutions to counter the setbacks of COPD therapy. The subsequent section covers state-of-the-art drug delivery technologies and novel drug formulations designed to enhance drug deposition and absorption in COPD lungs. It further explores a methodical yet coordinated explanation of targeted personalized therapies and emerging approaches, including nanoparticles, polymeric carriers, and vesicular delivery systems. Towards the end, the book discusses ongoing and completed clinical trials encompassing the management of COPD through advanced drug delivery approaches. It serves as a valuable resource for professionals, scientists, academicians, and clinicians specializing in respiratory health.
Provides an in-depth understanding of the epidemiology, etiology, and pathophysiology of Chronic Obstructive Pulmonary Disease (COPD).
Delve into pathways responsible for COPD progression, conducting a detailed analysis of established biomarkers and potential targets in contemporary COPD therapy.
Offer insights into ongoing treatment modalities, evaluating their efficacy, drawbacks, and proposing prospective solutions to counter the setbacks of COPD therapy.
Systematically organizes information on state-of-the-art drug delivery technologies and novel formulations designed to enhance drug deposition and absorption in COPD lungs.
Presents a methodical explanation of targeted personalized therapies and emerging approaches, including nanoparticles, polymeric carriers, and vesicular delivery systems.
Dr. Parteek Prasher, an Associate Professor in the Department of Chemistry at the University of Petroleum & Energy Studies, possesses 8 years of research experience in medicinal chemistry and biomaterials. Leading a research team, he focuses on developing rationally designed molecules to target various disorders, including inflammation, cancer, and antimicrobial multidrug resistance. Dr. Prasher has received prestigious fellowships and awards, including the Junior/Senior Research Fellowship by the Council of Scientific and Industrial Research (2012–2015) and the TARE Fellowship by the Department of Science and Technology-Science and Engineering Research Board (DST-SERB) for three years. Dr. Mousmee Sharma, an Assistant professor in the Department of Chemistry at Uttaranchal University, possesses over 5 years of research experience in physical chemistry and biomaterials, with a focus on bio membranes. Her recent research centres on developing mucoadhesive materials for drug delivery across physiological mucus barriers. Dr. Mousmee, a 'Gold Medallist' in post-graduation, has authored 80 research and review articles and 20 book chapters in reputable journals Dr. Gang Liu completed his Bachelor of Science in Biotechnology at Tianjin University of Commerce in 2008, followed by a Master of Science in Biotechnology at the University of Wollongong in 2011. He earned his PhD in Immunology and Microbiology at the University of Newcastle (Australia) in 2016, focusing on airway remodeling in respiratory diseases such as chronic obstructive pulmonary disease (COPD), severe asthma, and idiopathic pulmonary fibrosis (IPF). Dr. Liu conducted postdoctoral research from 2016–2017, investigating inflammation's role in respiratory diseases, and later studied tissue structure changes and remodeling in the gut-lung crosstalk at Hunter Medical Research Institute (HMRI) from 2017–2019. Since 2019, he has held a tenure position as a lecturer at the University of Technology (UTS), leading the fibrosis program at the Center for Inflammation in the UTS/Centenary Institute. Dr. Liu was awarded a CREATE Hope Fellowship from Lung Foundation Australia (2022-2023) and was promoted to senior lecturer at UTS in early 2023. Currently, he teaches and coordinates immunology and pathology subjects at UTS while supervising three PhD students. His ongoing research focuses on understanding the mechanisms of lung fibrosis in various lung diseases and identifying new therapeutic options. Dr. Amlan Chakraborty specializes in unraveling the mechanisms of innate immune cells in airway inflammation and remodeling linked to chronic allergic airway diseases, particularly asthma. He holds a research master's degree and a PhD, focusing on developing immunomodulators to target airway inflammation in acute lung injury and asthma. As a postdoctoral research associate, he investigated peptide-conjugated nanoparticles in asthma-related inflammation. Joining the Fibrosis Group at Monash Biomedicine Discovery Institute in 2020, he secured two industry-funded fellowships to explore induced pluripotent stem cells' role in pulmonary fibrosis and understand epithelial cell repair in chronic allergic airway disease. Dr. Chakraborty has over 20 publications, 7 pending patents, and has attracted $200K in commercial funding. His post-PhD research concentrates on using nanoparticles, including serelaxin-conjugated ones, to attenuate airway inflammation and target airway remodelling in pulmonary fibrosis and asthma. He also investigates the role of pulmonary myeloid cells in asthma-associated airway remodeling using functionalized nanoparticles, traceable through innovative imaging techniques. Recently, he has expanded his research interest to explore circadian mechanisms in asthma. Dr. Kamal Dua, Associate Professor, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), has over 12 years of research experience working in the field of drug delivery targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Center for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua research in two complementary areas: drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as interleukins and microRNAs and developing new and effective drug delivery formulations for the management of inflammation in chronic airway diseases and cancer.
Chapter 1: Introduction to COPD: Epidemiology, Etiology, and Pathophysiology
Chapter 2: Biomarkers for the Management of Chronic Obstructive Pulmonary Disease
Chapter 3: Current Treatment Modalities for Chronic Obstructive Pulmonary Disease: Challenges and Limitations
Chapter 4: Inhaled Drug Delivery Systems in the Management of Chronic Obstructive Pulmonary Disease
Chapter 5: Advancements in Smart Inhaler Technology for Enhancing Chronic Obstructive Pulmonary Disease Care
Chapter 6: Nanotechnology in Pulmonary Drug Delivery
Chapter 7: Liposomal Drug Delivery in the Management of Chronic Obstructive Pulmonary Disease
Chapter 8: Polymeric Nanoparticles for Targeted Therapy of Chronic Obstructive Pulmonary Disease
Chapter 9: Hybrid Nanocarriers for the Delivery of Therapeutics in Chronic Obstructive Pulmonary Disease
Chapter 10: Dendrimers as Emerging Drug Carriers in Chronic Obstructive Pulmonary Disease
Chapter 11: Biodegradable Polymers for Controlled Release of Drugs in Chronic Obstructive Pulmonary Disease
Chapter 12: Nano-Approaches for the Delivery of Biologics in Chronic Obstructive Pulmonary Disease
Chapter 13: Nano Theranostics for Chronic Obstructive Pulmonary Disease: Status and Implications
Chapter 14: Senolytics: A Potential Therapeutic Approach for COPD Management
Chapter 15: Precision Care: Personalized Medicine in Chronic Obstructive Pulmonary Disease Management
Chapter 16: Digital Health Solutions: Enhancing Medication Adherence in COPD Treatment
Chapter 17: Clinical Trials and Regulatory Issues of Nanocarriers Employed in the Treatment of Chronic Obstructive Pulmonary Disease
Chapter 18: Prospects of Advanced Drug Delivery Systems in Combating Chronic Obstructive Pulmonary Disease
| Erscheint lt. Verlag | 26.3.2025 |
|---|---|
| Zusatzinfo | 17 Tables, black and white; 16 Line drawings, color; 2 Line drawings, black and white; 16 Illustrations, color; 2 Illustrations, black and white |
| Verlagsort | London |
| Sprache | englisch |
| Maße | 178 x 254 mm |
| Themenwelt | Studium ► 2. Studienabschnitt (Klinik) ► Pharmakologie / Toxikologie |
| Technik | |
| ISBN-10 | 1-032-81259-1 / 1032812591 |
| ISBN-13 | 978-1-032-81259-5 / 9781032812595 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
